Literature DB >> 14654925

N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.

Heeyeong Cho1, Woo Jean Kim, You Mie Lee, Young-Mi Kim, Young-Guen Kwon, Yong Suk Park, Eu-Yul Choi, Kyu-Won Kim.   

Abstract

Non-collagenous (NC-1) fragments at the C-terminus of basement membrane collagen IV, XV and XIII have been implicated as negative regulators of angiogenesis. Endostatin is an endogenous carboxyl-terminal fragment of collagen XVIII/NC-1, suppressing endothelial cell proliferation, migration in vitro and tumor growth in mouse models. Endostatin can bind zinc through N- and C-terminal residues. Here we demonstrate that N-/C-terminal deleted derivative of human endostatin, H5, effectively inhibited the proliferation of human umbilical vein endothelial cells (HUVECs). Also, tube formation in vitro was comparably inhibited either by H5 or endostatin. The anti-angiogenic and anti-tumorigenic activities of H5 and endostatin were confirmed by an in vivo assay using chick chorioallantoic membrane (CAM) and mouse models, respectively. Treatment of 30 ng of H5 inhibited the capillary formation in CAM by 50%. In addition, H5 exhibited more potent anti-tumor activity than wild-type endostatin in in vivo mouse metastasis assay. These results indicate that the N-/C-terminal deletion mutant would be a strong candidate of anti-cancer agent against spontaneous tumor development and growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14654925

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Structure-activity relationships of the human prothrombin kringle-2 peptide derivative NSA9: anti-proliferative activity and cellular internalization.

Authors:  Hyun Sook Hwang; Dong Won Kim; Soung Soo Kim
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

Review 2.  Decoding the Matrix: Instructive Roles of Proteoglycan Receptors.

Authors:  Thomas Neill; Liliana Schaefer; Renato V Iozzo
Journal:  Biochemistry       Date:  2015-07-22       Impact factor: 3.162

Review 3.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

4.  Specific targeting of gene expression to a subset of human trabecular meshwork cells using the chitinase 3-like 1 promoter.

Authors:  Paloma B Liton; Xialin Liu; W Daniel Stamer; Pratap Challa; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-01       Impact factor: 4.799

Review 5.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

6.  Hypoxia-induced increase of endostatin in murine aorta and lung.

Authors:  Renate Paddenberg; Petra Faulhammer; Anna Goldenberg; Wolfgang Kummer
Journal:  Histochem Cell Biol       Date:  2006-02-08       Impact factor: 4.304

7.  Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease.

Authors:  Michael Sponder; Monika Fritzer-Szekeres; Rodrig Marculescu; Brigitte Litschauer; Jeanette Strametz-Juranek
Journal:  Heart Vessels       Date:  2015-12-11       Impact factor: 2.037

8.  Exercise increases serum endostatin levels in female and male patients with diabetes and controls.

Authors:  Michael Sponder; Daniela Dangl; Stephanie Kampf; Monika Fritzer-Szekeres; Jeanette Strametz-Juranek
Journal:  Cardiovasc Diabetol       Date:  2014-01-06       Impact factor: 9.951

Review 9.  The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.

Authors:  Abbas Mohajeri; Sarvin Sanaei; Farhad Kiafar; Amir Fattahi; Majid Khalili; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2017-04-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.